Gossamer Bio to Present at Cantor Global Healthcare Conference
Gossamer Bio reported $48.5M in revenue and a $170.4M net loss for fiscal 2025.
See the full GOSS financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.
Gossamer Bio to Present at Cantor Global Healthcare Conference
Gossamer Bio is scheduled to present its pulmonary hypertension program at the Cantor Global Healthcare Conference with both webcast and 1x1 meetings.
SAN DIEGO--(BUSINESS WIRE)--
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the Cantor Global Healthcare Conference to take place on September 9-11, 2026.
Cantor Global Healthcare Conference
Date / Time: September 9th, at 10:55 AM ET
Format: Presentation & 1x1’s
Location: NYC, NY Webcast Link: Here
About Gossamer Bio
Gossamer Bio is a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with pulmonary hypertension.
For Investors and Media
Bryan Giraudo, Chief Financial Officer & Chief Operating Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com
Source: Gossamer Bio, Inc.
Key Terms
pahmedical
Pulmonary arterial hypertension (PAH) is a chronic condition in which the small blood vessels that carry blood from the heart to the lungs become narrowed or stiff, raising pressure and forcing the heart to work harder—like trying to squeeze water through a narrowed garden hose. It matters to investors because drug development, clinical trial outcomes, regulatory approvals and pricing decisions for PAH therapies can create significant revenue opportunities or financial risks for biotech and pharmaceutical companies operating in this therapeutic area.
ph-ildmedical
PH-ILD stands for pulmonary hypertension associated with interstitial lung disease, a condition where stiff or scarred lung tissue makes it harder to move oxygen into the blood and causes dangerously high blood pressure in the lung arteries. Investors care because it signals a serious, progressive illness with limited treatment options, shaping demand for therapies, clinical trial design, regulatory review and long-term revenue potential in respiratory and cardiovascular drug markets.
